Is Osler Diagnostics The Next Theranos Or Can It Surprise Everyone?
Founded with a vision to change point-of-care diagnostics, Osler Diagnostics has raised nearly $200m to develop and commercialize a platform that promises to revolutionize diagnostics with just a drop of a patients’ blood.
You may also be interested in...
Diagnostics such as c-reactive protein tests are more sensitive than ever before, but manufacturers are still struggling to place them in primary care and community settings where they can make huge differences.
Since closing its $245m funding raise, Quanta Dialysis Technologies has been scaling up its commercial infrastructure and bolstering its US presence.
Elizabeth Holmes has been convicted on four counts of investor fraud. Two attorneys who followed the case spoke to Medtech Insight about what happened – and what it could mean for industry as a whole.